.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Deloitte
Moodys
Covington
Cipla
Daiichi Sankyo
Harvard Business School
Healthtrust
Cantor Fitzgerald

Generated: November 21, 2017

DrugPatentWatch Database Preview

Pharmacia And Upjohn Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACIA AND UPJOHN, and what generic alternatives to PHARMACIA AND UPJOHN drugs are available?

PHARMACIA AND UPJOHN has one hundred and thirty-six approved drugs.

There are nine US patents protecting PHARMACIA AND UPJOHN drugs.

There are two hundred and eleven patent family members on PHARMACIA AND UPJOHN drugs in forty-six countries and sixty-six supplementary protection certificates in thirteen countries.

Summary for Pharmacia And Upjohn

International Patents:211
US Patents:9
Tradenames:110
Ingredients:85
NDAs:136
Drug Master File Entries: 41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
OGEN
estropipate
CREAM;VAGINAL084710-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DEPO-PROVERA
medroxyprogesterone acetate
INJECTABLE;INJECTION012541-003Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CAVERJECT
alprostadil
INJECTABLE;INJECTION020379-002Jul 6, 1995APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
IDAMYCIN
idarubicin hydrochloride
INJECTABLE;INJECTION050661-001Sep 27, 1990DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
XANAX
alprazolam
TABLET;ORAL018276-004Nov 27, 1985ABRXYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
XANAX XR
alprazolam
TABLET, EXTENDED RELEASE;ORAL021434-002Jan 17, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
MICRONASE
glyburide
TABLET;ORAL017498-001May 1, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
SOLU-CORTEF
hydrocortisone sodium succinate
INJECTABLE;INJECTION009866-003Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
SOLU-CORTEF
hydrocortisone sodium succinate
INJECTABLE;INJECTION009866-004Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION050639-001Aug 30, 1989APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pharmacia And Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
CAVERJECT
alprostadil
INJECTABLE;INJECTION020379-001Jul 6, 1995► Subscribe► Subscribe
Pharmacia And Upjohn
MICRONASE
glyburide
TABLET;ORAL017498-001May 1, 1984► Subscribe► Subscribe
Pharmacia And Upjohn
TYMTRAN
ceruletide diethylamine
INJECTABLE;INJECTION018296-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Pharmacia And Upjohn
NICOTROL
nicotine
INHALANT;ORAL020714-001May 2, 1997► Subscribe► Subscribe
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 1996► Subscribe► Subscribe
Pharmacia And Upjohn
GLYNASE
glyburide
TABLET;ORAL020051-003Sep 24, 1993► Subscribe► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-011Jan 27, 1998► Subscribe► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-013Jan 27, 1998► Subscribe► Subscribe
Pharmacia And Upjohn
GENOTROPIN PRESERVATIVE FREE
somatropin recombinant
INJECTABLE;INJECTION020280-004Aug 24, 1995► Subscribe► Subscribe
Pharmacia And Upjohn
CAVERJECT
alprostadil
INJECTABLE;INJECTION020379-002Jul 6, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PHARMACIA AND UPJOHN drugs

Drugname Dosage Strength Tradename Submissiondate
linezolid
Injection2 mg/mL, 100 mL bag
ZYVOX
12/29/2009
linezolid
Injection2 mg/mL, 300 mL bag
ZYVOX
9/1/2009
linezolid
Oral Suspension100 mg/5 mL
ZYVOX
8/3/2009
tolterodine tartrate
Extended-release Capsules2 mg and 4 mg
DETROL LA
7/30/2007
linezolid
Tablets600 mg
ZYVOX
12/21/2005
colestipol hydrochloride
Tablets1 g
COLESTID
8/23/2005

Non-Orange Book Patents for Pharmacia And Upjohn

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,057,292 Method for inhibiting growth hormone action► Subscribe
6,013,478 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,004,931 Method for inhibiting growth hormone action► Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► Subscribe
6,451,561 Growth hormone variants► Subscribe
5,750,373 Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants► Subscribe
5,780,279 Method of selection of proteolytic cleavage sites by directed evolution and phagemid display► Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,780,613 Growth hormone variants► Subscribe
5,834,598 Human growth hormone variants► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pharmacia And Upjohn Drugs

Country Document Number Estimated Expiration
European Patent Office0851925► Subscribe
European Patent Office1200065► Subscribe
Slovakia12092002► Subscribe
Czech Republic20023750► Subscribe
Austria412413► Subscribe
China1418097► Subscribe
TaiwanI256310► Subscribe
Austria354390► Subscribe
Canada2001774► Subscribe
MexicoPA02007471► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pharmacia And Upjohn Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
204Luxembourg► Subscribe91204, EXPIRES: 20171113
C0018France► SubscribePRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
2015000093Germany► SubscribePRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
C/GB96/053United Kingdom► SubscribePRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
2004004,C0717738Lithuania► SubscribePRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
2009004Lithuania► SubscribePRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
C/GB01/025United Kingdom► SubscribePRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
C0004Belgium► SubscribePRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Cipla
Queensland Health
Teva
Merck
US Department of Justice
Argus Health
Chinese Patent Office
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot